Recent investigations into retatruptide peptide demonstrate promising potential for managing obesity and type diabetes mellitus. The peptide, a dual stimulator of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide, looks to offer greater body mass and glycemic management compared existing medications. Additional patient studie